Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier

Journal of Invasive Cardiology

Volumn 12, Issue 2, 2000, Pages 109-112

  Desai, Milind ^a   Lucore, Charles L ^a  

^a Prairie Cardiovascular Consultants Ltd   (United States)

Author keywords

Abciximab; Thrombocytopenia; Tirofiban

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TIROFIBAN; TYROSINE;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CORONARY BLOOD VESSEL; HUMAN; MALE; MIDDLE AGED; STENT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CORONARY VESSELS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOCYTOPENIA; TYROSINE;

EID: 0034132118     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Jubelirer S, et al. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy. Am J Hematology 1999;61:205-208.
2. Berkowitz S, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-319.
3. McClellan K, et al. Tirofiban: A review of its use in acute coronary syndromes. Drugs 1998;56:1067-1080.
4. King S, et al. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: The RESTORE investigators. Circulation 1997;96:1445-1453.
5. Jordan R, et al. Preclinical development of c7E3 Fab: A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA (Ed). Adhesion Receptors as Therapeutic Targets. New York: CRC Press, 1996: pp. 281-302.
6. Aguirre F, et al. for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
7. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
8. Coller, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991;614:192-213.
9. Frelinger A, et al. Selective inhibition of integrin function by antibodies specific for ligand-occupted receptor conformers. J Biol Chem 1990;265:6346-6352.
10. Tcheng JE, et al. Readministration of abciximab: Interim report of the ReoPro readministration registry. Am Heart J 1999;138:S33-S38.